Marketed in 48 countries across Europe, Latin America, the Middle East, and Oceania, Imigran is a globally distributed brand of sumatriptan succinate, classified within the serotonergic, antimigraine, and analgesic categories. It is one of the more recognisable migraine-specific brands an international traveller is likely to encounter, and this page is written for readers trying to identify it abroad — whether they already use it at home, have just been prescribed it in a new country, or have spotted the name on a pharmacy shelf and want to confirm what it is.
Imigran is indicated for the treatment of migraine. The structured indication block further down this page reflects the registered use as recorded across the markets where the brand circulates, and the medication sits within a class of agents developed specifically for migraine attacks rather than for general pain relief.
The brand's wide footprint means a traveller may encounter it under the same name in markets including Germany, Brazil, Australia, Denmark, and Egypt, but regulatory packaging, prescription requirements, and available presentations differ from country to country. In some markets the same active ingredient is sold under other brand names, and a local pharmacist can usually identify a sumatriptan-containing product on the regional formulary even where the Imigran name is not used.
Other molecules in the broader antimigraine-serotonergic class are also distributed internationally under various brand names, though they are not freely interchangeable, since members of the class differ in onset profile and clinical positioning. A pharmacist in the destination country can point to what is registered locally. Decisions about starting, continuing, or substituting any migraine medication belong with a healthcare provider who knows the patient's history.
Imigran is prescribed for the treatment of migraine. Its active ingredient belongs to a class of serotonergic agents developed specifically for migraine attacks rather than for general pain or fever, which distinguishes it from over-the-counter analgesics that share part of the same therapeutic territory. The full registered indication as recorded by national regulators is shown in the structured section below this introduction.
Imigran contains sumatriptan succinate, classified within the antimigraine, serotonergic, and analgesic categories. Sumatriptan is the same molecule whether sold as Imigran or under other commercial names, and it circulates internationally under several brand names — particularly in markets where the original patent has expired and multiple manufacturers produce sumatriptan-containing products in parallel.
Imigran is registered in 48 countries, spanning Europe, Latin America, parts of the Middle East and Africa, and Oceania. Examples include Australia, Brazil, Germany, Egypt, Denmark, Colombia, and the Czech Republic. If your country is not represented in this list, a local pharmacist can usually confirm whether sumatriptan is available in that market under another brand name or as a generic.
Sumatriptan is sold under several brand names worldwide, especially in markets where the original patent has expired and generic manufacturers have entered. Other molecules in the broader antimigraine-serotonergic class also exist internationally, though they are not freely interchangeable — class members differ in onset and clinical positioning. To identify a local sumatriptan-containing product, search the active ingredient on Pill2Trip or ask a pharmacist.
Yes. Imigran is a prescription medication in most jurisdictions where it is registered, and migraine-specific therapy is calibrated to the individual patient's pattern of attacks, history, and concurrent medications. This matters particularly for travellers and people relocating between countries, since prescription rules, available presentations, and even the brand name on the box can differ. Any decision to start, switch, or substitute should involve a healthcare provider.
